ValuEngine upgraded shares of Becton Dickinson and (NYSE:BDX) from a hold rating to a buy rating in a report released on Tuesday.
A number of other analysts have also commented on the company. JPMorgan Chase & Co. raised Becton Dickinson and from a neutral rating to an overweight rating and set a $175.00 target price for the company in a research report on Thursday, June 21st. Citigroup raised Becton Dickinson and from a neutral rating to a buy rating and boosted their target price for the company from $237.00 to $251.00 in a research report on Tuesday, April 10th. BMO Capital Markets began coverage on Becton Dickinson and in a research report on Monday, March 5th. They issued a market perform rating and a $249.00 target price for the company. Finally, Zacks Investment Research lowered Becton Dickinson and from a buy rating to a hold rating in a research report on Tuesday, March 6th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $237.29.
Shares of Becton Dickinson and opened at $239.50 on Tuesday, Marketbeat Ratings reports. The stock has a market capitalization of $63.49 billion, a PE ratio of 25.26, a price-to-earnings-growth ratio of 1.65 and a beta of 1.12. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.12 and a current ratio of 1.70. Becton Dickinson and has a 1 year low of $191.53 and a 1 year high of $248.39.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.63 by $0.02. The company had revenue of $4.22 billion for the quarter, compared to the consensus estimate of $4.12 billion. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The firm’s revenue was up 42.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.30 EPS. equities research analysts forecast that Becton Dickinson and will post 10.99 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 8th will be issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date of this dividend is Thursday, June 7th. Becton Dickinson and’s dividend payout ratio is currently 31.65%.
In other Becton Dickinson and news, insider Alexandre Conroy sold 20,128 shares of the business’s stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $228.74, for a total transaction of $4,604,078.72. Following the completion of the sale, the insider now directly owns 35,583 shares of the company’s stock, valued at approximately $8,139,255.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David F. Melcher acquired 500 shares of the firm’s stock in a transaction on Monday, May 7th. The shares were bought at an average cost of $225.07 per share, with a total value of $112,535.00. Following the completion of the acquisition, the director now directly owns 2,728 shares in the company, valued at approximately $613,990.96. The disclosure for this purchase can be found here. Insiders own 1.00% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of BDX. Almanack Investment Partners LLC. bought a new position in shares of Becton Dickinson and in the fourth quarter valued at approximately $109,000. BDO Wealth Advisors LLC grew its holdings in shares of Becton Dickinson and by 361.6% in the first quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock valued at $125,000 after acquiring an additional 452 shares in the last quarter. Truewealth LLC bought a new position in shares of Becton Dickinson and in the fourth quarter valued at approximately $133,000. Wagner Wealth Management LLC bought a new position in shares of Becton Dickinson and in the fourth quarter valued at approximately $154,000. Finally, Icon Wealth Partners LLC bought a new position in shares of Becton Dickinson and in the fourth quarter valued at approximately $156,000. 84.08% of the stock is owned by hedge funds and other institutional investors.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.